News

Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty
Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...
EquityBulls3d
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...
Pharmabiz3d
Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US
Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US: Our Bureau, Bengaluru Wednesday, July 16, 2025, 1 ...
Biocon Biologics Expands Diabetes Portfolio With FDA Approval Of Kirstytm, The First And Only Interchangeable Rapid-Acting Insulin Aspart In The United States
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight
Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...
pharmaphorum4d
MSD says subcutaneous Keytruda matches IV form
A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...